Pardo RZ, Perdomo MR

Language: Spanish
References: 45
Page: 105-116
PDF size: 81.21 Kb.

ABSTRACT

A literature review was made in Pubmed database, making emphasis on papers published in the last decade. The subject headings for this search were glucans, glucans recognition, glucans biological activitiy, glucans pharmaceuticals. On the basis of the available information, the main aspects related to this topic were analyzed and shown in this paper. β-(1→3)-glucans are glucose-derived polymers found mainly in the cellular wall of fungi, yeasts and plants. They are considered pathogensassociated molecular patterns that are ecognized by several receptors, being dectin-1 the key recognition receptor of these structures. Some authors have underlined their Immunomodulating properties. It has been demonstrated that they synergize and potentate the actions of Toll-like receptor ligands on the release of proinflammatory cytokines, though β-(1→3)-glucans have shown an antinflamatory profile which greatly depends on their structural characteristics. β-(1→3)-glucans are important pollutants stemming from cellulose depth filters used in clarification process of parenteral blood derivatives. For this reason, it is necessary to study the consequences of their presence in parenterals. This review summarized the main aspects related with the recognition and biological activities of β-(1→3)-glucans as well as it delved into studies on their presence in blood derivatives as main pollutant. Finally, the paper underlined the role of Monnocyte Activation Test to detect β-(1→3)- glucans in parenterals.

REFERENCES

1. Brown G, Gordon S. Immune recognition of fungal b-glucans. Cell Microbiol. 2005;7(4):471.9.

2. Medzhitov R, Janeway C. Innate Immunity. N Engl J Med. 2000;343:338-44.

3. Soltanian S, Stuyven E, Cox E, Sorgeloos P, Bossier P. Beta-glucans as immunostimulant in vertebrates and invertebrates. Crit Rev Microbiol. 2009;35(2):109-38.

4. Usami M, Ohata A, Horiuchi T, Nagasawa K, Wakabayashi T, Tanaka S. Positive (1→3)-β-D-glucan in blood components and release of (1→3)-β-D-glucan from depthtype membrane filters for blood processing. Transfusion. 2002;42:1189-95.

5. Nagasawa K, Yano Y, Kitabayashi G, Morimoto H, Yamada Y, Ohata O, et al. Experimental proof of contamination of blood components by (1→3)-β-D-glucan caused by filtration with cellulose filters in the manufacturing process. J Artif Organs. 2003;6:49-54.

6. Ohata A, Usami M, Horiuchi T, Nagasawa K. Release of (1→3)-β-D-Glucan from Depth-type Membrane Filters and Their in vitro Effects on Proinflammatory Cytokine Production. Artificial Organs. 2003;27(8):728-35.

7. Ochiai M, Yamamoto A, Naito S, Maeyama J, Masumi A, Hamaguchi I, et al. Applicability of bacterial endotoxins test to various blood products by the use of endotoxin-specific lysates. Biologicals. 2010:38:629-36.

8. Buchacher A, Krause D, Wiry G, Weinberger J. Elevated Endotoxin Levels in Human Intravenous Immunoglobulin Concentrates Caused by (1->3)-{beta}-D-Glucans. PDA J Pharm Sci Technol. 2010;64:536-44.

9. Brown G, Gordon S. A new receptor for b-glucans. Nature. 2001;413:36-7.

10. Tsoni V, Brown G. β-Glucans and Dectin-1. Ann NY Acad Sci. 2008;1143:45-60.

11. Goodridge H, Wolf A, Underhill D. Beta-glucan recognition by the innate immune system. Immunol Rev. 2009;230(1):38-50.

12. Reid D, Gow N, Brown G. Pattern recognition: recent insights from Dectin-1. Curr Opin Immunol. 2009;21(1):30-7.

13. Taylor P, Brown G, Reid D, Martínez-Pomares L, Gordon S, Wong S. The betaglucan receptor, Dectin-1, is predominantly expressed on the surface of cells of the monocyte-macrophage and neutrophyl line cells. J Immunol .2002;269:3876-82.

14. Willment J, Brown G, Gordon S. Characterisation of the human beta-glucan receptor and its alternatively spliced isoforms. J Biol Chem. 2001;276:43818-23.

15. Brown G, Gordon S. Fungal beta-glucans and mammalian Immunity. Immunity. 2003;19:311-5.

16. Hoekstra M, Van Berkel TJC, Van Eck M. Scavenger receptor BI: A multi-purpose player in cholesterol and steroid metabolism. World J Gastroenterol. 2010;16(47):5916-24.

17. Rice P, Kelley J, Kogan G, Ensley H, Kalbfleisch J, Browder I, et al. Human monocyte scavenger receptors are pattern recognition receptors for (1→3)-beta-Dglucans. J Leukoc Biol. 2002;72:140-6.

18. Thornton B, Vetvicka V, Pitman M, Goldman R, Ross G. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol. 1996;156:1235-46.

19. van Bruggen R, Drewniak A, Jansen M, van Houdt M, Roos D, Chapel H, et al. Complement receptor 3, not Dectin-1, is the major receptor on human neutrophils for beta-glucan-bearing particles. Mol Immunol. 2009;47(2-3):575-81.

20. Hahn P, Evans S, Kottom T, Standing J, Pagano R, Limper A. Pneumocystis carinii cell wall beta-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism. J Biol Chem. 2003;278:2043-50.

21. Herre J, Gordon S, Brow, GD. Dectin-1 and its role in the recognition of betaglucans by macrophages. Mol Immunol. 2004;40:86976.

22. Williams D, Li C, Ha T, Ozment-Skelton T, Kalbfleisch J, Preiszner J, Brooks L, et al. Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis. J Immunol. 2004;172:44956.

23. Engstad Ch, Engstad R, Olsen J, Osterud B. The effect of soluble h-1,3-glucan and lipopolysaccharide on cytokine production and coagulation activation in whole blood. Int Immunopharmacol. 2002;2:1585-97.

24. Kikkert R, Bulder I, de Groot E, Aarden L, Finkelman M. Potentiation of Toll-like receptor-induced cytokine production by (1→3)-β-D-glucans: implications for the monocyte activation test. J Endotoxin Res. 2007;13(3):140-9.

25. Nakagawa Y, Ohno N, Murai T. Suppression by Candida albicans beta-glucan of cytokine release from activated human monocytes and from T cells in the presence of monocytes. J Infect Dis. 2003;187:710-13.

26. Luhm J, Langenkamp U, Hensel J, Frohn Ch, Brand G, Hennig H, et al. β-(1→3)-Dglucan modulates DNA binding of nuclear factors κB, AT and IL-6 leading to an antiinflammatory shift of the IL-1β/IL-1receptor antagonist ratio. BMC Immunol. 2006;7:5.

27. Suda M, Ohno N, Adachi Y, Yadomae T. Tissue distribution of intraperitoneally administered (1→3)-beta-D-glucan (SSG), a highly branched antitumor glucan, in mice. J Pharmacobiodyn. 1992;15:417-26.

28. Suda M, Ohno N, Hashimoto T, Koizumi K, Adachi Y, Yadomae T. Kupffer cells play important roles in the metabolic degradation of a soluble anti-tumor (1→3)-beta-Dglucan, SSG, in mice. FEMS Immunol Med Microbiol. 1996;15:93-100.

29. Miura T, Ohno N, Miura N, Shimada S, Yadomae T. Inactivation of a particle β- glucan by proteins in plasma and serum. Biol Pharm Bull 1997;20:1103-7.

30. Murphy E, Davis J, Carmichael M. Immune modulating effects of β-glucan. Curr Opin Clin Nutr Metab Care. 2010;13(6):656-61.

31. Hong F, Yan J, Baran J, Allendorf D, Hansen R, Ostroff G, et al. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol. 2004;173:797-806.

32. Rice P, Adams E, Ozment-Skelton T, Gonzalez A, Goldman M, Lockhart B, et al. Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J Pharmacol Exp Ther. 2005;314:1079-86.

33. Li B, Cai Y, Qi C, Hansen R, Ding C, Mitchell TC, Yan J. Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer. Clin Cancer Res. 2010;16(21):5153-64.

34. Takahashi H, Ohno N, Adachi Y, Yadomae T. Association of immunological disorders in lethal side effect of NSAIDs on beta-glucan-administered mice. FEMS Immunol Med Microbiol. 2001;31:1-14.

35. Douwes J. (1→3)-Beta-D-glucans and respiratory health: a review of the scientific evidence. Indoor Air. 2005;15:160-9.

36. Yoshitomi H, Sakaguchi N, Kobayashi K, Brown GD, Tagami T, Sakihama T, et al. A role for fungal β-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J Exp Med. 2005;201:949-60.

37. Yoshida K, Nakajima M, Yamasaki M, Kitano Y, Niki Y, Ohsawa G, et al. Investigation of the influence of hemodialysis membranes and factors associated with hemodialysis on serum (1→3)-β-D-glucan. Kansenshogaku Zasshi. 1998;72:245-8.

38. Kanda H, Kubo K, Hamasaki K, Kanda Y, Nakao A, Kitamura T, et al. Influence of various hemodialysis membranes on the plasma (1→3)-β-D-glucan level. Kidney Int. 2001;60:31923.

39. Kato A, Takita T, Furuhashi M, Takahashi T, Maruyama Y, Hishida A. Elevation of blood (1→3)-β-D-glucan concentrations in hemodialysis patients. Nephron. 2001;89:15-9.

40. Hoffman O, Olson E, Limper A. Fungal beta-glucans modulate macrophage release of tumor necrosis factor-alpha in response to bacterial lipopolysaccharide. Immunol Lett. 1993;37:19-25.

41. Masihi K, Madaj K, Hintelmann H, Gast G, Kaneko Y. Down-regulation of tumor necrosis factor-alpha, moderate reduction of interleukin-1beta, but not interleukin-6 or interleukin-10, by glucan immunomodulators curdlan sulfate and lentinan. Int J Immunopharmacol. 1997;19:463-8.

42. Pearson F, Bohon J, Lee W, Bruszer G, Sagona M, Jakubowski G, et al. Characterization of Limulus Amoebocyte Lysate-Reactive Material from Hollow-Fiber Dialyzers. Environ Microbiol Rep. 1984;48:1189-96.

43. Perdomo-Morales R, Pardo-Ruiz Z, Spreitzer I, Lagarto A, Montag T. Monocyte Activation Test (MAT) reliably detects pyrogens in parenteral formulations of Human Serum Albumin. ALTEX. 2011;28:227-35.

44. Finkelman M. Glucatell™-A New Kit for Quantitative Determination of (1→3)-β-DGlucan. LAL Update. 2001;19:1-4.

45. Tsuchiya M, Asahi N, Suzuoki F, Ashida M, Matsuura S. Detection of peptidoglycan and L-glucan with silkworm larvae plasma test. FEMS Immunol Med Microbiol. 1996;15:129-34.